Filtered By:
Source: American Heart Journal
Education: Study
This page shows you your search results in order of relevance. This is page number 10.
Order by Relevance | Date
Total 295 results found since Jan 2013.
Documentation of study medication dispensing in a prospective large randomized clinical trial: Experiences from the ARISTOTLE Trial
Conclusions: Rates of medication dispensing error were low and balanced between treatment groups. The initially reported dispensing error rate was the result of data recording and data management errors and not true medication dispensing errors. These analyses confirm the previously reported results of ARISTOTLE.
Source: American Heart Journal - August 19, 2013 Category: Cardiology Authors: John H. Alexander, Elliott Levy, Jack Lawrence, Michael Hanna, Anthony P. Waclawski, Junyuan Wang, Robert M. Califf, Lars Wallentin, Christopher B. Granger Tags: Electrophysiology Source Type: research
African American race but not genome-wide ancestry is negatively associated with atrial fibrillation among postmenopausal women in the Women's Health Initiative
Conclusion: African American race is significantly and inversely correlated with AF in postmenopausal women. The etiology of this association remains unclear and may be related to unidentified environmental differences. Larger studies are necessary to identify genetic determinants of AF in African Americans.
Source: American Heart Journal - August 9, 2013 Category: Cardiology Authors: Marco V. Perez, Thomas J. Hoffmann, Hua Tang, Timothy Thornton, Marcia L. Stefanick, Joseph C. Larson, Charles Kooperberg, Alex P. Reiner, Bette Caan, Carlos Iribarren, Neil Risch Tags: Electrophysiology Source Type: research
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease
Sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, lowers blood glucose when administered as monotherapy or in combination with other antihyperglycemic agents. TECOS will evaluate the effects of adding sitagliptin to usual diabetes care on cardiovascular outcomes and clinical safety. TECOS is a pragmatic, academically run, multinational, randomized, double-blind, placebo-controlled, event-driven trial recruiting approximately 14,000 patients in 38 countries who have type 2 diabetes (T2DM), are at least 50 years old, have cardiovascular disease, and have an hemoglobin A1c value between 6.5% and 8.0%. Eligible participan...
Source: American Heart Journal - October 25, 2013 Category: Cardiology Authors: Jennifer B. Green, M. Angelyn Bethel, Sanjoy K. Paul, Arne Ring, Keith D. Kaufman, Deborah R. Shapiro, Robert M. Califf, Rury R. Holman Tags: Trial Design Source Type: research
Radial versus femoral approach comparison in percutaneous coronary intervention with intraaortic balloon pump support: The RADIAL PUMP UP Registry
Background: The role of intraaortic balloon pump (IABP) during percutaneous coronary intervention (PCI) in high-risk acute patients remains debated. Device-related complications and the more complex patient management could explain such lack of clinical benefit. We aimed to assess the impact of transradial versus transfemoral access for PCI requiring IABP support on vascular complications and clinical outcome.Methods: We retrospectively analyzed 321 consecutive patients receiving IABP support during transfemoral (n = 209) or transradial (n = 112) PCI. Thirty-day net adverse clinical events (NACEs) (composite of postprocedu...
Source: American Heart Journal - October 14, 2013 Category: Cardiology Authors: Enrico Romagnoli, Maria De Vita, Francesco Burzotta, Bernardo Cortese, Giuseppe Biondi-Zoccai, Francesco Summaria, Roberto Patrizi, Chiara Lanzillo, Valerio Lucci, Caterina Cavazza, Fabio Tarantino, Giuseppe M. Sangiorgi, Ernesto Lioy, Filippo Crea, Sunil Tags: Interventional Cardiology Source Type: research
Growth differentiation factor 15 and cardiovascular events in patients with stable ischemic heart disease (The Heart and Soul Study)
Background: Growth differentiation factor 15 (GDF-15) is a relatively new biomarker that predicts mortality in patients with chronic stable angina or acute coronary syndrome. However, the association of GDF-15 with cardiovascular (CV) events and the mechanisms of this association are not well understood.Methods: We measured plasma GDF-15 and cardiac disease severity in 984 patients with stable ischemic heart disease who were recruited for the Heart and Soul Study between September 2000 and December 2002. Subsequent CV events (myocardial infarction, stroke, and CV death), hospitalization for heart failure, and all-cause mor...
Source: American Heart Journal - December 9, 2013 Category: Cardiology Authors: David W. Schopfer, Ivy A. Ku, Mathilda Regan, Mary A. Whooley Tags: Coronary Artery Disease Source Type: research
Balloon aortic valvuloplasty in the era of transcatheter aortic valve replacement: Acute and long-term outcomes
Background: The use of balloon aortic valvuloplasty (BAV) has resurged since the development of transcatheter aortic valve replacement (TAVR). The aim of our study was to determine the procedural and long-term outcomes of patients treated by BAV in the early TAVR era.Methods: From 2005 to 2008, 323 consecutive patients presenting with severe aortic stenosis were treated by BAV in our institution.Results: Mean age and logistic EuroSCORE were 80.5 ± 9.9 years and 28.7% ± 12.5%, respectively. The effective orifice area increased from 0.68 ± 0.25 to 1.12 ± 0.39 cm2 (P
Source: American Heart Journal - November 6, 2013 Category: Cardiology Authors: Hélène Eltchaninoff, Eric Durand, Bogdan Borz, Akira Furuta, Karim Bejar, Alexandre Canville, Ali Farhat, Chiara Fraccaro, Matthieu Godin, Christophe Tron, Rahul Sakhuja, Alain Cribier Tags: Valvular and Congenital Heart Disease Source Type: research
Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial
Conclusions: PEGASUS-TIMI 54 is investigating whether the addition of intensive antiplatelet therapy with ticagrelor to low-dose aspirin reduces major adverse cardiovascular events in high-risk patients with a history of myocardial infarction.
Source: American Heart Journal - January 8, 2014 Category: Cardiology Authors: Marc P. Bonaca, Deepak L. Bhatt, Eugene Braunwald, Marc Cohen, Philippe Gabriel Steg, Robert F. Storey, Peter Held, Eva C. Jensen, Marc S. Sabatine Tags: Trial Design Source Type: research
Rationale and design of The Intracoronary Stenting and Antithrombotic Regimen—Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oraL anticoagulant therapy following drug-Eluting stenting (ISAR-TRIPLE) study
Background: An increasing number of patients undergoing coronary stenting need lifelong anticoagulation and therefore require a triple therapy typically consisting of aspirin, clopidogrel, and a vitamin K antagonist. Triple therapy confers an elevated bleeding risk as compared with dual therapy; however, omission of either antiplatelet or anticoagulation therapy might increase the risk of stent thrombosis or thrombembolic events. Although guidelines recommend a duration of dual antiplatelet therapy of 6 to 12months after drug-eluting stent (DES) implantation, the optimal duration of dual antiplatelet therapy in patients re...
Source: American Heart Journal - January 16, 2014 Category: Cardiology Authors: K. Anette Fiedler, Robert A. Byrne, Stefanie Schulz, Dirk Sibbing, Julinda Mehilli, Tareq Ibrahim, Michael Maeng, Karl-Ludwig Laugwitz, Adnan Kastrati, Nikolaus Sarafoff Tags: Trial Design Source Type: research
Scar tissue–guided left ventricular lead placement for cardiac resynchronization therapy in patients with ischemic cardiomyopathy: An acute pressure-volume loop study
Background: Response to cardiac resynchronization therapy (CRT) is hampered by the extent and location of left ventricular (LV) scar tissue. It is commonly advised to avoid scar tissue while placing the LV lead. However, whether individual patients benefit from this strategy remains unclear.Methods: Thirty-two CRT candidates with ischemic cardiomyopathy were enrolled from 2 successive clinical trials (TBS and E-pot study). Magnetic resonance imaging with late contrast enhancement was performed to assess location, degree and transmurality of LV scar tissue. Patients underwent invasive pressure-volume loop measurements to as...
Source: American Heart Journal - January 16, 2014 Category: Cardiology Authors: Gerben Jan de Roest, LiNa Wu, Carel C. de Cock, Matthijs L. Hendriks, Peter Paul H.M. Delnoy, Albert C. van Rossum, Cornelis P. Allaart Tags: Heart Failure Source Type: research
Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: Findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry
Conclusions: Contraindications to OAC therapy among patients with AF are common but subjective. Many patients with reported contraindications were receiving OAC, suggesting that the perceived benefit outweighed the potential harm posed by the relative contraindication.
Source: American Heart Journal - January 6, 2014 Category: Cardiology Authors: Emily C. O'Brien, DaJuanicia N. Holmes, Jack E. Ansell, Larry A. Allen, Elaine Hylek, Peter R. Kowey, Bernard J. Gersh, Gregg C. Fonarow, Christopher R. Koller, Michael D. Ezekowitz, Kenneth W. Mahaffey, Paul Chang, Eric D. Peterson, Jonathan P. Piccini, Tags: Electrophysiology Source Type: research
Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion
The objective of this study is to explore the efficacy and safety of rivaroxaban 20 mg once daily (15 mg if creatinine clearance is 30-49 mL/min) compared with dose-adjusted vitamin K antagonists (VKAs; international normalized ratio 2.0-3.0) in patients scheduled for elective cardioversion.Methods: This is a prospective, randomized, open-label, parallel group comparison of approximately 1,500 patients from 17 countries with hemodynamically stable nonvalvular atrial fibrillation of>48 hours or unknown duration. Patients will be randomized 2:1 (rivaroxaban:VKA) using 2 cardioversion strategies: the first approach is early c...
Source: American Heart Journal - January 16, 2014 Category: Cardiology Authors: Michael D. Ezekowitz, Riccardo Cappato, Allan L. Klein, A. John Camm, Chang-Sheng Ma, Jean-Yves Le Heuzey, Mario Talajic, Maurício I. Scanavacca, Panos E. Vardas, Paulus Kirchhof, Stefan H. Hohnloser, Melanie Hemmrich, Vivian Lanius, Isabelle Ling Meng, Tags: Trial Design Source Type: research
Prognosis of elderly patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention in 2001 to 2011: A report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) registry
Conclusions: The prognosis of patients older than 80 years treated with primary PCI for STEMI was relatively unchanged during the 10-year inclusion period, despite changes in patient characteristics and treatment. Advanced age increased the risk of adverse events, but survivors of the early phase after PCI had a slightly improved prognosis compared with the general population.
Source: American Heart Journal - February 27, 2014 Category: Cardiology Authors: Matthijs A. Velders, Stefan K. James, Berglind Libungan, Giovanna Sarno, Ole Fröbert, Jörg Carlsson, Martin J. Schalij, Per Albertsson, Bo Lagerqvist Tags: Acute Ischemic Heart Disease Source Type: research
Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Background: Atrial fibrillation (AF) is the most common cardiac dysrhythmia and contributes significantly to health care expenditures. We sought to assess the frequency and predictors of hospitalization in patients with AF.Methods: The ORBIT-AF registry is a prospective, observational study of outpatients with AF enrolled from June 29, 2010, to August 9, 2011. The current analysis included 9,484 participants with 1-year follow-up. Multivariable, logistic regression was used to identify baseline characteristics that were associated with first cause-specific hospitalization.Results: Overall, 31% of patients with AF studied (...
Source: American Heart Journal - February 19, 2014 Category: Cardiology Authors: Benjamin A. Steinberg, Sunghee Kim, Gregg C. Fonarow, Laine Thomas, Jack Ansell, Peter R. Kowey, Kenneth W. Mahaffey, Bernard J. Gersh, Elaine Hylek, Gerald Naccarelli, Alan S. Go, James Reiffel, Paul Chang, Eric D. Peterson, Jonathan P. Piccini Tags: Electrophysiology Source Type: research
Sex difference in clinical outcomes after percutaneous coronary intervention in Korean population
Conclusion: Among Korean population undergoing contemporary PCI, women have a significantly higher risk of short- and long-term major cardiovascular events than do men but have better long-term survival.
Source: American Heart Journal - January 16, 2014 Category: Cardiology Authors: Duk-Woo Park, Young-Hak Kim, Sung-Cheol Yun, Jung-Min Ahn, Jong-Young Lee, Soo-Jin Kang, Seung-Whan Lee, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park Tags: Interventional Cardiology Source Type: research
PROspective Multicenter Imaging Study for Evaluation of chest pain: Rationale and design of the PROMISE trial
Conclusion: Multispecialty community practice enrollment into a large pragmatic trial of diagnostic testing strategies is both feasible and efficient. The PROMISE trial will compare the clinical effectiveness of an initial strategy of functional testing against an initial strategy of anatomical testing in symptomatic patients with suspected CAD. Quality of life, resource use, cost-effectiveness, and radiation exposure will be assessed.
Source: American Heart Journal - March 20, 2014 Category: Cardiology Authors: Pamela S. Douglas, Udo Hoffmann, Kerry L. Lee, Daniel B. Mark, Hussein R. Al-Khalidi, Kevin Anstrom, Rowena J. Dolor, Andrzej Kosinski, Mitchell W. Krucoff, Daniel W. Mudrick, Manesh R. Patel, Michael H. Picard, James E. Udelson, Eric J. Velazquez, Lawton Tags: Trial Design Source Type: research
